Cancer in pets, much like in humans, is a significant health concern, characterized by the uncontrolled growth of abnormal cells. The manifestations of cancer in animals can be quite similar to those seen in humans, including the development of tumors, weight loss, lethargy, and changes in appetite or behavior. However, the aging process in pets happens more rapidly, meaning cancers can develop and progress faster in animals compared to humans. Early detection of lumps and bumps in your pet is the key to a positive cancer treatment plan.
How IsoPet® Works:
IsoPet® Precision Radionuclide Therapy™ (PRnT) is an innovative treatment using highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The product delivers therapeutic radiation from within the tumor without the associated side effects of mainstream cancer treatments such as external-beam radiation therapy. Also known as PRnT™, the treatment uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area, delivering therapeutic radiation from within the tumor. Vivos Inc. has developed a Yttrium-90 based injectable device to treat tumors in animals (IsoPet® Division) and humans (RadioGel™ Division, not currently approved for human use). Vivos Inc. holds the international trademark for IsoPet® Precision Radionuclide Therapy™ which uses Yttrium-90 to kill tumors from the inside out and is revolutionizing the treatment of cancer.
Yttrium-90’s Role In Cancer Treatment:
Yttrium-90 (Y-90) is a radioactive isotope commonly used in radionuclide therapy, particularly for cancer treatment. Y-90 emits beta radiation, which is effective for treating certain types of cancers because of its ability to deliver high doses of radiation to localized areas with minimal impact on surrounding healthy tissue. The use of Y-90 allows for high precision in targeting tumors, reducing the risk of side effects typically associated with external beam radiation. The treatment planning involves sophisticated imaging techniques to ensure accurate delivery of the radioactive material. Y-90 therapy is effective in extending survival and improving the quality of life for pet patients with specific types of cancer, making it a valuable option in the oncological toolkit. Killing tumors from the inside out allows for safer delivery of the higher doses needed for treating both non-resectable and radiation resistant cancers.
IsoPet™ is a Safe Cancer Treatment
IsoPet® delivers more than 90% of its therapeutic radiation within 10 days of a single treatment. IsoPet® kills the tumor from the inside out with a prescribed dose of 400 Gy (gray). Other therapies may require six weeks or more to deliver the full course of radiation therapy.
IsoPet® is a Same Day Cancer Treatment
IsoPet® therapy is performed as an out-patient procedure and your pet may return home without subsequent concern for radiation exposure to your family.
IsoPet® has less Side Effects than Traditional Cancer Treatments
IsoPet® is administered directly into the tumor without harm to the surrounding tissues or organs. Your pet will feel minimal side effects of treatment.
IsoPet® and Y-90 Research
Current research is focused on improving the delivery and efficacy of Y90 therapy. Innovations such as personalized dosimetry, which tailors the radiation dose to the individual patients characteristics, are being explored. Below are two studies you may click the underlined title to read more.
Direct Interstitial Treatment of Solid Tumors Using an Injectable Yttrium-90-Polymer Composite
Darrell R. Fisher, Janean Fidel, and Charles A. Maitz
Yttrium-90 (90Y)-polymer composite (radiogel) may be administered directly into cancerous tissues to deliver highly localized beta radiation for therapy. In a dose-escalation study, the authors investigated the feasibility of treating feline and canine soft-tissue sarcomas as a model for nonresectable solid tumors in humans to gain clinical experience and to identify optimal methods for placing the composite uniformly within target tumor tissue. To read more click here.
Radiation Safety for Yttrium-90-polymer Composites (RadioGel™) in Therapy of Solid Tumors
Darrell R. Fisher
Yttrium-90 (90Y)-polymer composite (RadioGel™) is a new cancer therapeutic agent for treating solid tumors by direct interstitial injection. The 90Y-composite comprises insoluble, microscopic yttrium-phosphate particles carried by a sterile, injectable water-polymer (hydrogel) solution that can be placed directly by needle injection into solid tumors. The yttrium-90-RadioGel™ agent was designed to provide a safe, effective, localized, high-dose beta radiation for treating solid tumors. The properties of 90Y-RadioGel™ also make it a relatively safe agent for health care personnel who prepare, handle, and administer the material. The purpose of this work was to demonstrate and characterize radiation safety of the injectable 90Y-RadioGel™ therapeutic agent. To read more click here.
Yttrium-90 (Y90) has emerged as a valuable tool in the arsenal of cancer treatment. It’s targeted approach, combined with a minimally invasive procedure, offers significant benefits over traditional cancer therapies. Ongoing research and technological advancements continue to enhance its safety and efficacy. As we look to the future, Y90 therapy holds promise for treating a broader range of cancers, potentially improving outcomes and quality of life for many pet patients.
The IsoPet® division on Vivos Inc. is currently treating animal cancer in eight clinics across the United States and is expanding quickly. Vista Veterinary Hospital in Kennewick, WA, University of Missouri in Columbia, MO, Johns Hopkins University Veterinary Clinical Trials Network in Baltimore, MD, New England Equine Practice in Patterson, NY, Myhre Equine Clinic in Rochester, NH, Hopkinton Animal Hospital in Hopkinton, NH, Indian Creek Veterinary Hospital in Fort Wayne, IN and the most recently certified University of Wisconsin in Madison, WI for Equine cancer treatment. For a full list of IsoPet® Regional Clinics visit https://isopet.com/our-regional-clinics
Vivos Inc plans to expand its regional clinics across the USA in 2024 with the hopes of saving more pets across the country. If you are a veterinarian and would like more information on bringing Isopet® into your practice please contact us at info@vivosinc.com
